Share Name Share Symbol Market Type Share ISIN Share Description
CREO MEDICAL GROUP PLC LSE:CREO London Ordinary Share GB00BZ1BLL44 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -12.00p -5.61% 202.00p 200.00p 204.00p 214.00p 202.00p 214.00p 72,250 16:26:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -8.9 -13.0 - 242.24

CREO MEDICAL Share Discussion Threads

Showing 1201 to 1225 of 1225 messages
Chat Pages: 49  48  47  46  45  44  43  42  41  40  39  38  Older
DateSubjectAuthorDiscuss
17/9/2018
19:57
Worth reminding ourselves of the significance of this bit from the RNS dated 21 August regarding US FDA approval of Speedboat RS2 ahead of schedule: "This FDA Clearance has been received ahead of schedule, with the FDA review process being completed in 49 calendar days from submission. Accordingly, Creo will now assess the necessary steps to bring forward the implementation of its commercial plans for the US." The prospect of the company delivering on its US operation is what's driving this. Given the unique nature of the technology and the associated IP a successful launch across the US could be hugely profitable for those who've got in early. And then there's the rest of the world..... To date the company's execution has been faultless. Game on.
lurki0
17/9/2018
08:14
can't see any reason why they can't keep rolling out throughout the rest of the world. And increase the range of their products. i.e the growth phase has barely started yet. This could well become a multi-billion £ med tech company in time (unless Pentax buy them out completely - which is highly likely imo)
someuwin
17/9/2018
07:39
More good news, but surely at some point the market cap is going to get too far ahead of where the company is? Can't keep this rate of growth up indefinitely..
dplewis1
17/9/2018
07:12
Creo Medical Group plc Extension of Distribution Agreement with Hoya Pentax Medical for the Asia-Pacific (APAC) region Creo Medical Education Programme to be initiated in APAC alongside Market Seeding beginning in Australia. Chepstow, Wales - 17 September 2018 - Creo Medical Group plc (AIM: CREO) ("Creo" or the "Company"), a medical device company focused on the emerging field of surgical endoscopy, today announces that it has entered into an addendum to its distribution agreement with Hoya Group, Pentax Medical ("Pentax"). Under the terms of the original distribution agreement, Creo granted Pentax the right to distribute Creo's Speedboat product and CROMA platform in the Asia Pacific region for 5 years subject to agreement of final terms by territory. The addendum further entrenches Creo's relationship with Pentax with firm commitment to roll out to various territories in conjunction with establishing Creo's Clinical Education Program and thereafter seeding the chosen markets. Australia will be the first Asia Pacific territory in which Pentax will establish Creo's Clinical Education Program and subsequently seed the market. Pentax will purchase a minimum quantity of CROMA advance energy platforms and Speedboat instruments with the first products expected to be shipped within 3 months. Furthermore, Creo has agreed to extend the term of Pentax's distribution rights in each territory in which Pentax establishes Creo's Clinical Education Programme for a period of 5 years from the date on which Creo's products are registered in such territory. Creo has commenced the regulatory registration process for its products in Australia and in conjunction with Pentax Creo has begun introducing doctors from Australia and other territories to the clinical education program here in Europe which will be rolled out into APAC in the coming months. CROMA's electrosurgical platform combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. Speedboat is the first product approved in a suite of tools under development to aid the endoscopist in minimally invasive surgery. The Speedboat device helps reduce the risks associated with alternative laparoscopic procedures, reducing the length of hospital stays and transferring therapy from the operating room to the endoscopy room. Craig Gulliford, Chief Executive Officer, commented: "The extension of our agreement with Pentax marks a significant milestone in the commercialisation of Speedboat, our lead product. Creo is dedicated to improving patient outcomes and helping clinicians by bringing advanced energy to the emerging field of surgical endoscopy. Speedboat is paving the way for our suite of GI devices under development. Our products are rapidly gaining traction in the endoscopic field and with Pentax as our partner in the Asia Pacific region, their expertise and knowledge will prove invaluable to Creo in these important markets and as we build our reputation worldwide." David Woods, President and CEO of Pentax Americas and M&A Director, commented: "As a leading supplier of innovative and advanced medical products for minimally invasive procedures we recognise the great potential of the CROMA platform and Speedboat. I am pleased that we have been able to deepen our relationship with Creo. Ultimately, under this expanded commercial agreement more patients will benefit from the power of precise cutting and controlled coagulation, leading to better clinical outcomes in an outpatient setting."
someuwin
16/9/2018
09:08
Got in early at launch on this one. Great company, a ton of patents and very good trial results. Engineering is excellent and has still quite some way to go with recent developments. But best of all, under the radar for most bigger investors so I doubt much market manipulation just yet. Could go ballistic once the rampers jump on board followed by the shorters. Looking forward to the next update.
drbob_ceng
14/9/2018
11:13
Not that much free float and those that do own them aren't selling..
dplewis1
14/9/2018
11:09
The rise is relentless.
someuwin
13/9/2018
08:11
Yup - great news today.
someuwin
13/9/2018
07:41
But before the interims you get more great news..
dplewis1
05/9/2018
17:53
Interims due at the end of this month !
masurenguy
31/8/2018
12:26
But directors sold at placing price, not market price, so perhaps more to that than meets the eye?
hausofmaus
31/8/2018
12:17
Baillie Gifford buying - good. Directors selling (see second RNS) - not so good.
someuwin
31/8/2018
12:11
Baillie Gifford on board..nice.
dplewis1
29/8/2018
13:14
Key Strengths Disruptive patented technology – Creo has developed a patented energy system that combines microwave and bi-polar radio frequency energy capable of delivering precise cut, coagulation and ablation for electrosurgery applications; Product platform with clear benefits – the CROMA platform is capable of delivering time and cost benefits over invasive surgical solutions allowing practitioners, in some indications, to diagnose and treat near simultaneously thus potentially avoiding the need for separate appointments at the diagnosis and treatment stages with the same patient; Rich product pipeline – the group has developed a broad product pipeline targeting high value market segments, enhancing existing techniques and which could offer effective new curative therapies; Patent estate and significant scientific know-how – the group has an established and growing IP portfolio including 76 granted patents and 184 pending patent applications as at 18 October 2016; Experienced team – the management team has been drawn from the surgical instrumentation market covering R&D, quality, regulatory approval and commercialisation; Established facilities with scale to meet near term requirements and with the capacity for growth – the group has dedicated locations for innovation, design and development as well as cleanroom manufacturing and assembly facilities; Partnerships and relationships with industry leaders – the group is working in collaboration with key opinion leaders in the medical device sphere building advocacy for its products; Capacity to distribute its products – Creo Medical has recently signed a five-year Distribution Agreement with HOYA Group PENTAX Medical giving the group the ability to distribute its products in multiple countries.
someuwin
28/8/2018
15:19
CREO number 12:https://www.ii.co.uk/analysis-commentary/aims-best-performers-2018-so-far-ii506648/
dplewis1
28/8/2018
14:39
New highs again.
someuwin
03/8/2018
11:00
Cenkos note from yesterday:Creo Medical has made strong progress since its IPO, achieving regulatory approvals for its products and first in-human application of its device to remove a colorectal lesion. We maintain the view that the company's ground-breaking technology, which facilitates a broad range of therapeutic interventions to be performed through an endoscope, will stimulate significant interest in the +$3bn global endoscopy market with minimal direct competition. We maintain our Buy recommendation.
dplewis1
01/8/2018
14:49
Would appear that the probability of real success in this enterprise is now deemed the more likely outcome. Hence the oversubscription and resultant share price climb. Yet again I must rue my hesitation to reload at a lower level.....
lurki0
01/8/2018
11:23
...And again.
someuwin
31/7/2018
16:38
Another good day for CREO with decent volumes to back it up as well. All time high close..
dplewis1
24/7/2018
09:37
Still want to move higher.
someuwin
16/7/2018
09:07
All buys so far today.
someuwin
16/7/2018
08:50
To be fair it's a bit of a false rise because of the closing print from Friday, plus the spread is pretty wide. But yes, I think the upside is good with the placing money done and more distribution agreements in the bag.
dplewis1
16/7/2018
08:41
New highs coming.
someuwin
13/7/2018
11:05
"As the Company's products become more widely placed and more clinicians trained, the utility of the devices is becoming increasingly recognised which has led to the Company being presented with potential acquisition opportunities.." This is an incredibly bullish RNS, it'll be very interesting to see who they target. Won't be too long to wait for news if they are notifying investors like this.
dplewis1
Chat Pages: 49  48  47  46  45  44  43  42  41  40  39  38  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180919 03:29:57